Filing Details
Ernexa Therapeutics Inc. (NASDAQ:ERNA) filed a Form 8-K with the Securities and Exchange Commission on July 02, 2026, disclosing a material event.
8k filedNASDAQ:ERNA
Ernexa Therapeutics Inc. (ERNA) Reports Material Event to SEC
Filing Details Ernexa Therapeutics Inc. (NASDAQ:ERNA) filed a Form 8-K with the Securities and Exchange Commission on July 02, 2026, disclosing a material event. Market Context…
Market Context
Ernexa Therapeutics Inc.'s stock currently trades at $6.27 with a market capitalization of $11.7M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Ernexa Therapeutics Inc.'s stock.
All SEC filings for Ernexa Therapeutics Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ERNA Stock Page
Frequently Asked Questions
Where can I read ERNA's SEC filings?
Browse all filings on our ERNA SEC filings page.
What types of SEC filings does Ernexa Therapeutics Inc. file?
Public companies like Ernexa Therapeutics Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.